BioTime, Inc. (NYSE: BTX) Starts Presentation at LD Micro Main Event
BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The company’s current clinical programs target three primary sectors; aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and a private company, AgeX Therapeutics. For more information, visit the company’s website…







